The first U.S. trials in people put CRISPR to the test in 2019
When it was unveiled in 2012, people had great hopes that the gene editor CRISPR/Cas9 could treat or even cure hundreds to thousands of genetic diseases. This year, researchers in the United States began testing the gene editor in people, a crucial first step in determining whether the technology can fulfill its medical promise.
These first clinical trials are testing CRISPR/Cas9’s safety and efficacy against cancer, blood disorders and one form of inherited blindness in people who already have the disease (SN: 8/31/19, p. 6). Many more such trials are expected to ...